Cargando…
Iranian Pulmonary Arterial Hypertension Registry
BACKGROUND: Idiopathic pulmonary arterial hypertension (IPAH) is a fatal disorder with a prevalence of 8.6 per million. We introduce a registry website for IPAH and PAH patients ( www.IPAH.ir) for access and efficient delivery of government-aided and subsidized antihypertensive medications. MATERIAL...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
National Research Institute of Tuberculosis and Lung Disease
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4629425/ https://www.ncbi.nlm.nih.gov/pubmed/26528365 |
_version_ | 1782398573690748928 |
---|---|
author | Masjedi, Mohammad Reza Fahimi, Fanak Sharif-Kashani, Babak Malek Mohammad, Majid Saliminejad, Leila Monjazebi, Fateme |
author_facet | Masjedi, Mohammad Reza Fahimi, Fanak Sharif-Kashani, Babak Malek Mohammad, Majid Saliminejad, Leila Monjazebi, Fateme |
author_sort | Masjedi, Mohammad Reza |
collection | PubMed |
description | BACKGROUND: Idiopathic pulmonary arterial hypertension (IPAH) is a fatal disorder with a prevalence of 8.6 per million. We introduce a registry website for IPAH and PAH patients ( www.IPAH.ir) for access and efficient delivery of government-aided and subsidized antihypertensive medications. MATERIALS AND METHODS: The IPAH registry was opened in November 2009. Information of IPAH and PAH patients with a username and password were uploaded in the site. Data entry was possible only via the physicians and healthcare organizations via internet that were given a personalized username and password for entry. Following the patients’ profile submission, a scientific committee composed of a cardiologist and a pulmonologist who were selected by the Ministry of Health of Iran (MOH), evaluated the data. The eligibility of the patient to receive the medications was confirmed after evaluation. If the patient was eligible, 82% of the Bosentan cost was paid by MOH. RESULTS: To date, one hundred and sixteen patients (82 females, 34 males) have been registered. The mean pulmonary artery pressure by right heart catheterization was 69.24±17 mmHg (ranging from 35 to 110 mmHg). CONCLUSION: The first online Iranian registry program for IPAH and PAH patients is believed to supply essential information for health care providers in the field. |
format | Online Article Text |
id | pubmed-4629425 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | National Research Institute of Tuberculosis and Lung Disease |
record_format | MEDLINE/PubMed |
spelling | pubmed-46294252015-11-02 Iranian Pulmonary Arterial Hypertension Registry Masjedi, Mohammad Reza Fahimi, Fanak Sharif-Kashani, Babak Malek Mohammad, Majid Saliminejad, Leila Monjazebi, Fateme Tanaffos Original Article BACKGROUND: Idiopathic pulmonary arterial hypertension (IPAH) is a fatal disorder with a prevalence of 8.6 per million. We introduce a registry website for IPAH and PAH patients ( www.IPAH.ir) for access and efficient delivery of government-aided and subsidized antihypertensive medications. MATERIALS AND METHODS: The IPAH registry was opened in November 2009. Information of IPAH and PAH patients with a username and password were uploaded in the site. Data entry was possible only via the physicians and healthcare organizations via internet that were given a personalized username and password for entry. Following the patients’ profile submission, a scientific committee composed of a cardiologist and a pulmonologist who were selected by the Ministry of Health of Iran (MOH), evaluated the data. The eligibility of the patient to receive the medications was confirmed after evaluation. If the patient was eligible, 82% of the Bosentan cost was paid by MOH. RESULTS: To date, one hundred and sixteen patients (82 females, 34 males) have been registered. The mean pulmonary artery pressure by right heart catheterization was 69.24±17 mmHg (ranging from 35 to 110 mmHg). CONCLUSION: The first online Iranian registry program for IPAH and PAH patients is believed to supply essential information for health care providers in the field. National Research Institute of Tuberculosis and Lung Disease 2015 /pmc/articles/PMC4629425/ /pubmed/26528365 Text en Copyright© 2015 National Research Institute of Tuberculosis and Lung Disease This work is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly. |
spellingShingle | Original Article Masjedi, Mohammad Reza Fahimi, Fanak Sharif-Kashani, Babak Malek Mohammad, Majid Saliminejad, Leila Monjazebi, Fateme Iranian Pulmonary Arterial Hypertension Registry |
title | Iranian Pulmonary Arterial Hypertension Registry |
title_full | Iranian Pulmonary Arterial Hypertension Registry |
title_fullStr | Iranian Pulmonary Arterial Hypertension Registry |
title_full_unstemmed | Iranian Pulmonary Arterial Hypertension Registry |
title_short | Iranian Pulmonary Arterial Hypertension Registry |
title_sort | iranian pulmonary arterial hypertension registry |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4629425/ https://www.ncbi.nlm.nih.gov/pubmed/26528365 |
work_keys_str_mv | AT masjedimohammadreza iranianpulmonaryarterialhypertensionregistry AT fahimifanak iranianpulmonaryarterialhypertensionregistry AT sharifkashanibabak iranianpulmonaryarterialhypertensionregistry AT malekmohammadmajid iranianpulmonaryarterialhypertensionregistry AT saliminejadleila iranianpulmonaryarterialhypertensionregistry AT monjazebifateme iranianpulmonaryarterialhypertensionregistry |